0001209191-19-059914.txt : 20191210 0001209191-19-059914.hdr.sgml : 20191210 20191210171820 ACCESSION NUMBER: 0001209191-19-059914 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191206 FILED AS OF DATE: 20191210 DATE AS OF CHANGE: 20191210 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Primiano Christopher Brett CENTRAL INDEX KEY: 0001603510 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36167 FILM NUMBER: 191278392 MAIL ADDRESS: STREET 1: C/O KARYOPHARM THERAPEUTICS INC. STREET 2: 85 WELLS AVENUE, SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc. CENTRAL INDEX KEY: 0001503802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263931704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 BUSINESS PHONE: 617-658-0600 MAIL ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-12-06 0 0001503802 Karyopharm Therapeutics Inc. KPTI 0001603510 Primiano Christopher Brett C/O KARYOPHARM THERAPEUTICS INC. 85 WELLS AVENUE NEWTON MA 02459 0 1 0 0 EVP, CBO, GC & Secretary Common Stock 2019-12-06 4 M 0 5000 6.54 A 11653 D Common Stock 2019-12-06 4 M 0 5000 10.39 A 16653 D Common Stock 2019-12-06 4 S 0 5000 17.4568 D 11653 D Common Stock 2019-12-06 4 S 0 5000 17.4512 D 6653 D Common Stock 2019-12-06 4 S 0 3000 17.456 D 3653 D Stock Option (right to buy) 6.54 2019-12-06 4 M 0 5000 0.00 D 2026-01-14 Common Stock 5000 13000 D Stock Option (right to buy) 10.39 2019-12-06 4 M 0 5000 0.00 D 2027-01-19 Common Stock 5000 108000 D These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Includes 3,772 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.34 to $17.61, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.35 to $17.62, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.345 to $17.685, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 15, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. /s/ Christopher B. Primiano 2019-12-10